Clinical Trials Browser

Phase 2 × Central Nervous System Neoplasms × 90 days × Clear all

NCT03210714 2026-03-19

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

CNSGastrointestinalGenitourinaryLymphoidMyeloid

Familial ependymoma, Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT03213652 2026-03-19

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Phase 2 Active not recruiting

13 enrolled

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT07462507 2026-03-10

Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1

Phase 2 Not yet recruiting

104 enrolled

CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms

NCT05425004 2026-03-05

Cabozantinib for Patients With Recurrent or Progressive Meningioma

Phase 2 Recruiting

24 enrolled

CNS

Meningioma, Central Nervous System Neoplasms

NCT03270059 2026-02-27

Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System

Phase 2 Recruiting

150 enrolled

CNS

Brain Neoplasms, Cranial Nerve Diseases, Central Nervous System Neoplasms

NCT06528691 2026-02-17

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

Phase 2 Recruiting

52 enrolled

CNS

Glioma, Central Nervous System Neoplasms

NCT03155620 2026-02-10

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Phase 2 Active not recruiting

1,376 enrolled

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Xanthogranuloma, Juvenile, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Histiocytic Sarcoma

NCT04992013 2026-01-23

Niraparib in Tumors Metastatic to the CNS

Phase 2 Active not recruiting

20 enrolled

CNS

Neoplasm Metastasis, Central Nervous System Neoplasms

NCT05267106 2025-12-30

FIGHT-209

Phase 2 Terminated

83 enrolled 18 charts

CNS

Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms

NCT06322342 2025-12-26

Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

Phase 2 Completed

18 enrolled

CNS

Neuroinflammatory Diseases, Brain Neoplasms, Glioma, Meningioma, Multiple Sclerosis, Neoplasms, Neurilemmoma, Neurofibroma, Neuroma, Acoustic, Central Nervous System Neoplasms